TransMedics Group is trading at $75.77, down 4.25%, during the October 14 session amid broad market pressure as September inflation data renewed concerns about interest rates and Treasury yields.
- Available coverage also cites elevated yields and CPI worries as part of the stock’s trading backdrop.
- No clear company-specific announcement explaining the move surfaced. Canaccord’s October 13 price-target reduction maintained a Buy rating and was not a clear direct catalyst.